Skip to content
naulon

Not checkedNot checked for notices yet.

Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome

Yeter Hasan H., Derici Ulver, Arinsoy Turgay and 3 more

Romanian Journal of Internal Medicine · 2022

doi:10.2478/rjim-2021-0034 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Introduction. The aim was to evaluate the effect of therapeutic plasma exchange (TPE) and eculizumab on hematological and renal survival in atypical hemolytic uremic syndrome (aHUS), and additionally, to examine the reliability of discontinuation of eculizumab treatment.

Abstract licence: CC BY-NC-ND

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.